ALA-3000, Long-acting Injectable of Ketamine for Treatment-resistant depression

Category:Finished Dosage > Nervous System Preparations
Product Name:ALA-3000, Long-acting Injectable of Ketamine for Treatment-resistant depression
CAS No.:NA
Standard:In-house Standards
Price(USD):Negotiable
Company:Alar Pharmaceuticals Inc.

Basic Info
  • Grade: pharmaceutical grade, injection grade

    Factory Location: Taiwan

    Main Sales Markets: North America,Western Europe,Australasia,Asia

  • Sample Provided: no

    Payment Terms: L/C

    Alar pharmaceuticals Inc is developing ALA-3000, a sustained release injectable of ketamine, indicating for treatment-resistant depression (TRD) subcutaneously. Through the controlled release formulation, it is anticipated that the pharmacokinetic profile without dumping/burst effect would reduce the risks of adverse events (e.g. dissociation, sedation, and perceptual changes) and improve patient compliance. 

    The preclinical studies for proof of concept and GMP production of drug substance and drug product have been completed. The pre-IND meeting with US FDA has also been completed, agreeing with the development plans of Chemistry, Manufacturing, and Controls (CMC), nonclinical studies, and phase 1 clinical study for ALA-3000, and also provides feedback beyond the studies required for opening phase 1 study. The outcomes of this pre-IND meeting deem the development of ALA-3000 through 505(b)(2) regulatory pathway and advance towards an IND submission. The IND submission for the first-in-human study is anticipated later 2022.

Send your message to this supplier
  • From:
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service